ERBB2 and Hyperglycemia: Given that DAPT-induced Notch inactivation attenuated hyperglycemia-induced Nrg1 overexpression, we hypothesized that the dual inhibition of NOTCH and HER2 could effectively reduce tumor burden, especially in breast cancer patients with hyperglycemia.